VCH-759

antiviral for therapy of hepatitis C infection

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Hepatitis C 07/01/2009 - "Evaluation of VCH-759 monotherapy in hepatitis C infection." 06/15/2014 - "The direct-acting antivirals (DAAs) currently in development for treatment of hepatitis C fall into four categories: (i) NS3/4A protease inhibitors: ABT-450/r, faldaprevir, asunaprevir, GS-9256, vedroprevir (GS-9451), danoprevir, MK-5172, vaniprevir, sovaprevir, ACH-2684, narlaprevir and simeprevir, in addition to those that are already developed [telaprevir (Incivek®) and boceprevir (Victrelis®)], (ii) NS5A protein inhibitors: ABT-267, daclatasvir, ledipasvir, ACH-2928, ACH-3102, PPI-668, AZD-7295, MK-8742, and GSK 2336805; (iii) NS5B (nucleoside-type) polymerase inhibitors: sofosbuvir (now approved by the FDA since 6 December 2013), GS-0938, mericitabine, VX-135, ALS 2158 and TMC 649128; (iv) NS5B (non-nucleoside-type) polymerase inhibitors: VX-222, ABT-072, ABT-333, deleobuvir, tegobuvir, setrobuvir, VCH-916, VCH-759, BMS-791325 and TMC-647055. "
2.	Infections 07/01/2009 - "Evaluation of VCH-759 monotherapy in hepatitis C infection."
3.	Hepatocellular Carcinoma (Hepatoma) 12/15/2019 - "Assessment of the anti-HCV activity (GT1a) using human hepatoma cell line (Huh-7.5) illustrates superior activity of 4e (EC50 = 3.80 μM) relative to VCH-759 (EC50 = 5.29 μM). "

1.	Proteins (Proteins, Gene)
2.	Nucleosides
3.	Antiviral Agents (Antivirals)
4.	HCV NS3-4A Protease Inhibitors
5.	Simeprevir
6.	Sofosbuvir
7.	dasabuvir
8.	8- cyclohexyl- N- ((dimethylamino)sulfonyl)- 1,1a,2,12b- tetrahydro- 11- methoxy- 1a- ((3- methyl- 3,8- diazabicyclo(3.2.1)oct- 8- yl)carbonyl)cycloprop(d)indolo(2,1- a)(2)benzazepine- 5- carboxamide
9.	ledipasvir
10.	ombitasvir